посттрансплантационный период

Успешная трансплантация аллогенного костного мозга у больных с тяжелым грамотрицательным сепсисом и септическим шоком

ТРАНСПЛАНТАЦИЯ КОСТНОГО МОЗГА , , , , , , , , , , ,

Г.М. Галстян, П.М. Макарова, Л.А. Кузьмина, Е.Н. Паровичникова, Г.А. Клясова, О.С. Покровская, М.Ю. Дроков, В.А. Новиков, В.В. Троицкая, И.Э. Костина, В.Г. Савченко

ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация

РЕФЕРАТ

Приводятся два клинических наблюдения успешной трансплантации аллогенного костного мозга у больных с тяжелым грамотрицательным сепсисом и септическим шоком. Описаны особенности течения посттрансплантационного периода, тактика ведения больных.

Ключевые слова: трансплантация аллогенных гемопоэтических стволовых клеток, кондиционирование, сепсис, септический шок, посттрансплантационный период, нейтропенический энтероколит, длительная нейтропения, синегнойная палочка, острая дыхательная недостаточность, инвазивный аспергиллез легких, искусственная вентиляция легких, неинвазивная вентиляция легких, мезенхимные стромальные клетки.

Читать статью в PDFpdficon

ЛИТЕРАТУРА

  1. Morena M.T., Gatti R.A. A History of Bone Marrow Transplantation. Hematol. Oncol. Clin. 2011; 25: 1–15.
  2. Wingard J.R., Majhail N.S., Brazauskas R. et al. Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation. J. Clin. Oncol. 2011; 29: 2230–9.
  3. Gyurkocza B., Rezvanil A., Storb R.F. Allogeneic hematopoietic cell transplantation: the state of the art. Exp. Rev. Hematol. 2010; 3(3): 285–99.
  4. Савченко В.Г., Любимова Л.С., Паровичникова Е.Н. и др. Трансплантации аллогенных и аутологичных гемопоэтических стволовых клеток при острых лейкозах (итоги 20-летнего опыта). Тер. арх. 2007; 79: 30–5. [Savchenko V.G., Lyubimova L.S., Parovichnikova Ye.N., et al. Transplantation of allogeneic and autologous hematopoietic stem cells in acute leukemias (summary of 20-year experience). Ter. arkh., 2007; 79: 30–5. (In Russ.)].
  5. Blume K.G., Forman S.J., Appelbaum F.R. The evaluation and counseling of candidates for hematopoietic cell transplantation. Thomas’ Hematopoietic Cell Transplantation, 3rd ed. Malden: Blackwell, 2004: 449–67.
  6. Ball E.D., Lister J., Law P. Evaluation of patients before hematopoietic stem cell transplantation. Hematopoietic Stem Cell Therapy. New York: Churchill Livingstone, 2001: 225–32.
  7. Majhail N.S., Rizzo J.D. Surviving the cure: long term follow up of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2013: 1–7.
  8. Soubani A.O., Kseibi E., Bander J.J. et al. Outcome and Prognostic Factors of Hematopoietic Stem Cell Transplantation Recipients Admitted to a Medical ICU. Chest 2004; 126(5): 1604–11.
  9. Marena C., Zecca M., Carenini M.L. et al. Incidence of, and risk factors for, nosocomial infections among hematopoietic stem cell transplantation recipients, with impact on procedure-related mortality. Infect. Control Hosp. Epidemiol. 2001; 22: 510–7.
  10. Huynh T.N., Weigt S.S., Belperio J.A., Territo M., Keane M.P. Outcome and Prognostic Indicators of Patients with Hematopoietic Stem Cell Transplants Admitted to the Intensive Care Unit. J. Transplant. 2009; 2009: 917294.
  11. Afessa B., Azoulay E. Critical Care of the Hematopoietic Stem Cell Transplant Recipient. Crit. Care Clin. 2010; 26: 133–50.
  12. Degoricija V., Sharma M., Legac A. et al. Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: impact of intensive care unit performance and antimicrobial therapy. Croat. Med. J. 2006; 47(3): 385–97.
  13. Shirazi M.H., Ranjbar R., Ghasemi A. et al. A Survey of Bacterial Infections in Bone Marrow Transplant Recipients. Iran. J. Publ. Health 2007; 36: 77–81.
  14. Ali N., Adil S.M., Shaikh M.U., Moosajee M., Masood N. Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Exper. Hematol. Oncol. 2012; 1: 13.
  15. George B., Mathews V., Srivastava A., Chandy M. Infections among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant. 2004; 33: 311–5.
  16. Donnelly P. Bacterial complications of transplantation: diagnosis and treatment. J. Antimicrob. Chemother. 1995; 36: 59–72.
  17. van Kraaij M.G., Dekker A.W., Verdonck L.F. et al. Infectious gastroenteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant. 2000; 26(3): 299–303.
  18. Schulenburg A., Turetschek K., Wrba F. et al. Early and late gastrointestinal complications after myeloablative and nonmyeloablative allogeneic stem cell transplantation. Ann. Hematol. 2004; 83(2): 101–6.
  19. Holler E., Kolb H.J., Greinix H. et al. Bleeding events and mortality in SCT patients: a retrospective study of hematopoietic SCT patients with organ dysfunctions due to severe sepsis or GVHD. Bone Marrow Transplant. 2009; 43(6): 491–7.
  20. Mikulska M., Del Bono V., Bruzzi P. et al. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection 2012; 40: 271–8.
  21. Legrand M., Max A., Peigne V. et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit. Care Med. 2012; 40(1): 43–9.
  22. Reikvam H., Hatfiel K.J., Kittang A.O., Hovland R., Bruserud O. Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. doi: 10.1155/2011/104631. Epub, May 3, 2011.
  23. Cho E.K., Bang S.M., Ahn J.Y. et al. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia. Korean J. Intern. Med. 2003; 18(1): 13–20.
  24. Программное лечение заболеваний системы крови. Под ред. В.Г. Савченко. М.: Практика, 2012: 720–34. [Programmnoye lecheniye zabolevaniy sistemy krovi. Pod red. V.G. Sav chenko (Program therapy for hematological malignancies. Ed. by: V.G. Savchenko). M.: Praktika, 2012: 720–34.]
  25. De Pauw B., Walsh T.J., Donnelly J.P. et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008; 46(12): 1813–21.
  26. Afessa B., Tefferi A., Dunn W.F. et al. Intensive care unit support and Acute Physiology and Chronic Health Evaluation III performance in hematopoietic stem cell transplant recipients. Crit. Care Med. 2003; 31(6): 1715–21.
  27. Leung A.N., Gosselin M.V., Napper C.H. et al. Pulmonary Infections after Bone Marrow Transplantation: Clinical and Radiographic Findings. Radiology 1999; 210: 699–710.
  28. Champlin R.E., Perez W.S., Passweg J.R. et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007; 109(10): 4582–5.
  29. Georges G.E., Storb R. Stem cell transplantation for aplastic anemia. Int. J. Hematol. 2002; 75(2): 141–6.
  30. Quenot J.P., Binquet C., Kara F., Martinet O. The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study. Crit. Care. 2013; 17: R65.
  31. Jawad I., Luksic I., Rafnsson S.B. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. Glob. Health 2012; 2(1): 10404.
  32. Ghosh I., Raina V., Kumar L. et al. Profile of infections and outcome in high-risk febrile neutropenia: experience from a tertiary care cancer center in India. Med. Oncol. 2012; 29: 1354–60.
  33. Klastersky J., Ameye L., Maertens J. et al. Bacteraemia in febrile neutropenic cancer patients. Int. J. Antimicrob. Agents 2007; 30: 51–9.
  34. Sakamoto M., Saruta K., Nakazawa Y. et al. Sepsis Associated with Hematological Malignancies: Prophylaxis of Pseudomonas aeruginosa Sepsis. 69th General Meeting of the Japanese Association for Infectious Diseases (Fukuoka). Kansenshogaku Zasshi 1996; 70(2): 116–22.
  35. Клясова Г.А. Инфекции при гемобластозах и депрессиях кроветворения: клиника, диагностика и лечение: Автореф. дис. ¼ д-ра мед. наук. М., 2009. [Klyasova G.A. Infektsii pri gemoblastozakh i depressiyakh krovetvoreniya: klinika, diagnostika i lechenie. Dokt. diss. (Infections in hematological malignancies and depressed hematopoiesis. Dr. med. sci. diss.). M., 2009]
  36. Mokart D., Craenenbroeck T. Prognosis of acute respiratory distress syndrome (ARDS) in neutropenic cancer patients. Eur. Respir. J. 2012; 40(1): 169–76.
  37. Regazzoni C.J., Irrazabal C., Luna C.M., Poderoso J.J. Cancer patients with septic shock: mortality predictors and neutropenia. Supp. Care Cancer 2004; 12: 833–9.
  38. Groeger J.S., Lemeyow S., Price K., Nierman J. Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model. Clin. Oncol. 1998; 16: 761–70.
  39. Gronlykke L., Brandstrup S.L., Perner A. Data from clinical database on septic shock are valid. Dan. Med. J. 2012; 59(10): A4522.
  40. Горелов В.Г. Эффективность искусственной вентиляции легких при острой дыхательной недостаточности у больных гемобластозами: Автореф. дис. ¼ канд. мед. наук. М., 1994. [Gorelov V.G. Effektivnost iskusstvennoy ventilyatsii legkikh pri ostroy dykhatelnoy nedostatochnosti u bolnykh gemoblastozami. Kand. diss. (Efficacy of mechanical lung ventilation in acute respiratory failure in patients with hematological malignancies. Cand med. sci.diss.). M., 1994]
  41. Бычинин М.В., Галстян Г.М., Шулутко Е.М., Клясова Г.А., Городецкий В.М. Катетеризация артерий у гематологических больных. Гематол. и трансфузиол. 2013; 58: 14–22. [Bychinin M.V., Galstyan G.M., Shulutko Ye.M., Klyasova G.A., Gorodetzky V.M. Artery catheterization in hematological patients. Gematol. i transfuziol. 2013; 58: 14–22. (In Russ.)].
  42. Shirley H., Mei J. Mesenchymal Stem Cells Reduce Inflammation while Enhancing Bacterial Clearance and Improving Survival in Sepsis. Am. J. Respir. Crit. Care Med. 2010; 182(8): 1047–57.
  43. Gilbert C., Vasu T.S., Baram M. Use of mechanical ventilation and renal replacement therapy in critically ill hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant. 2013; 19(2): 321–4.
  44. Azoulay E., Alberti C., Bornstain C. et al. Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support. Crit. Care Med. 2001; 29(3): 519–25.
  45. Avivi I., Oren I., Haddad N., Rowe J.M. Stem Cell Transplantation Post Invasive Fungal Infection Is a Feasible Task. Am. J. Hematol. 2004; 75: 6–11.
  46. Bjerke J.W., Meyers J.D., Bowden R.A. Hepatosplenic candidiasis — a contraindication to marrow transplantation? Blood 1994; 84: 2811–4.
  47. Wang J.T., Yao M., Tang J.L., Chang S.C., Hung C.C. Prior invasive fungal infection is not a contraindication for subsequent allogeneic bone marrow transplantation in adult patients with hematologic malignancies. J. Clin. Oncol. 2001; 19(1): 4000–1.
  48. Aki Z.S., Sucak G.T., Yegin Z.A. et al. Hematopoietic Stem Cell Transplantation in Patients With Active Fungal Infection: Not a Contraindication for Transplantation. Transplant. Proceed. 2008; 40: 1579–85.
  49. El-Cheikh J., Castagna L., Wang L. et al. Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk. Lymphoma 2010; 51(9): 1705–10.
  50. Lee J.Y., Jung C.W., Kim K., Jang J.H. Impact of previous invasive pulmonary aspergillosis on the outcome of allogeneic hematopoietic stem cell transplantation. Korean J. Hematol. 2012; 47(4): 255–9.
  51. Dellinger R.P., Levy M.M., Rhodes A. et al. Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012. Intens. Care Med. 2013; 39(2): 165–228.
  52. Pittenger M.F., Mackay A.M., Beck S.C. et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–7.
  53. Deans R.J., Moseley A.B. Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol. 2000; 28: 875–84.
  54. Jones B.J., McTaggart S.J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp. Hematol. 2008; 36: 733–41.
  55. Петинати Н.А. Профилактика реакции трансплантат против хозяина у больных гемобластозами после трансплантации аллогенных гемопоэтических стволовых клеток с помощью мультипотентных мезенхимальных стромальных клеток донора: Автореф. дис. ¼ канд. мед. наук. М., 2013. [Petinati N.A. Profilaktika reaktsii transplantat protiv khozyaina u bolnykh gemoblastozami posle transplantatsii allogennykh gemopoeticheskikh stvolovykh kletok s pomoshchyu multipotentnykh mezenkhimalnykh stromalnykh kletok donora. Kand. diss. (Prevetion of graft-versus-host disease in patients with hematological malignancies after transplantation of allogeneic hematopoietic stem cells using multipotent mesenchymal stromal donor cells. Cand med. sci. diss.). M., 2013].
  56. Kuzmina L.A., Petinati N.A., Parovichnikova E.N. et al. Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease — A Phase II Study. Stem Cells Int. 2012; 2012: 968213.
  57. Kebriaei P., Robinson S. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy 2011; 13(3): 262–8.
  58. Lucchini G., Dander E., Rovelli A. et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graftversus-host disease in a pediatric population. Biol. Blood Marrow Transplant. 2010; 16: 1293–301.
  59. Toubai Т., Paczesny S., Shono Y. et al. Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation. Curr. Stem Cell Res. Ther. 2009; 4: 252–9.
  60. Osuchowski M.F., Welch K., Siddiqui J., Remick D.G. Circulating cytokine/inhibitor profiles reshape the understanding of the sirs/cars continuum in sepsis and predict mortality. J. Immunol. 2006; 177: 1967–74.
  61. Chien M.H., Bien M.Y., Ku C.C. et al. Systemic human orbital fat-derived stem/stromal cell transplantation ameliorates acute inflammation in lipopolysaccharide-induced acute lung injury. Crit. Care Med. 2012; 40(4): 1245–53.
  62. Kim E.S., Sil Y. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates Escherichia coli induced acute lung injury in mice. Respir. Res. 2011; 12: 108.
  63. Adult stem cell transplantation in severe blood poisoning. 2011-MSC-1 Erasmus MC Rotterdam. http://www.trialregister.nl/ 64. OHRI, Ottawa to lead first stem cell therapy trial for septic shock/2012. http://nationalhealthwatch.ca/